Sign in
Not yet taking people in United StatesPhase 2

Imaging to spot early tumor response in triple negative breast cancer before surgery

Tests ultrasound-based imaging in adults with triple negative breast cancer having treatment before surgery.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the site
Trial code
Registry title
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
Status
Not yet recruiting
Phase
Phase 2
People taking part
32 people, planned
Starts
1 Jan 2027
Expected to end
31 Dec 2028
Type of study
Interventional
Treatments tested
  • Elastography
  • Magnetic Resonance Imaging
  • Photoacoustic Imaging
  • Ultrasound Imaging
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel
  • Doxorubicin
  • Cyclophosphamide
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage II-III triple negative breast cancer who will have immunotherapy with chemotherapy before surgery. It tests new imaging to see early how the tumor responds.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Stage II-III triple negative breast cancer, with no signs of metastatic disease.
Earlier treatment
Clinically appropriate for the KEYNOTE-522 regimen, based on performance status and laboratory findings.
Biomarker or test result
Triple negative breast cancer, per ASCO-CAP guidelines.

Main reasons for not taking part

  • Acute bacterial or fungal infection needing IV antibiotics at registration
  • Pregnant or breastfeeding
  • Expecting to conceive or father children during the trial
  • Positive pregnancy test at screening

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Patients with stage II-III triple negative breast cancer, per American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines
  • Deemed clinically appropriate for KEYNOTE-522 regimen based on performance status and laboratory findings
  • No signs of metastatic disease
  • Female patients must have a negative urine or serum pregnancy at screening (pregnancy test is not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are > 1 year postmenopausal)
  • All patients of reproductive potential must agree to use an approved form of contraception
  • Must provide informed consent

Who cannot take part

  • Acute bacterial or fungal infection requiring intravenous (IV) antibiotics at time of registration
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial

Where in United States

  • Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesContact: Obi EzenniaNot yet recruiting

About the trial

What the trial wants to find out

This clinical trial studies how well ultrasound/photoacoustic/elasticity (US/PA/E) imaging works for early identification of tumor response in patients with stage II-III triple-negative breast cancer receiving immunotherapy and chemotherapy before surgery (neoadjuvant). US imaging uses high-energy sound waves to look at tissues and organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen. PA imaging delivers laser light into tissue which produces ultrasonic waves which are then converted into images. Elastography (i.e., elasticity [E]) imaging uses sound waves to send vibrations into a specific organ and measures how fast those vibrations move. The vibrations move faster through areas of stiff tissue and a computer uses these measurements to make an image of those areas. Combined US/PA/E imaging using the Vevo F2 and Vevo LAZR-X20 devices may be safe and provide earlier information about tumor response to standard neoadjuvant immunotherapy and chemotherapy than current standard imaging.

The group in the trial

  • Diagnostic (US/PA/E)Treatment being tested

    Patients undergo US imaging using the Vevo F2 device and PA/E imaging using the Vevo LAZR-X20 device prior to and at week 4 and week 7 of SOC carboplatin, pembrolizumab, and paclitaxel regimen, prior to cycles 1 and 2 of SOC doxorubicin, cyclophosphamide, pembrolizumab regimen, as well as prior to SOC surgery. Patients also undergo breast MRI on study.

    Treatment: Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging, Ultrasound Imaging, Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, and Cyclophosphamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Undergoing Neoadjuvant Immunotherapy With Chemotherapy
Plain-language title
Imaging to spot early tumor response in triple negative breast cancer before surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026